Myeloma specialists from the Czech Republic have published clinical trial results that shed further light on chromosomal abnormalities and their impact on survival in newly diag­nosed multiple myeloma patients.

Specifically, the researchers found that patients with three or more chromos­omal abnor­malities, a gain in the 1q21 region, or the trans­location t(4;14) have reduced survival compared to patients without such abnormalities.

According to the researchers, their findings highlight the importance of chromosomal abnormalities when considering treatment options for myeloma patients.

They note, however, that their findings need to be confirmed in a pro­spective, …

A recent study showed that maintenance therapy with thalidomide and interferon delayed progression, but did not extend survival, in elderly multiple myeloma patients. Additionally, the thalidomide-interferon maintenance therapy caused slightly more side effects than maintenance therapy with interferon alone.

Previous studies have indicated that in younger patients, maintenance therapy with thalidomide (Thalomid) after stem cell transplantation resulted in increased progression-free survival time in all trials and in increased overall survival time in two out of five trials (see related Beacon news 1, 2, and 3).

However, it was …